• Nie Znaleziono Wyników

The Voice of the Editor-in-Chief


Academic year: 2022

Share "The Voice of the Editor-in-Chief"

Pokaż więcej ( Stron)

Pełen tekst



The Voice of the Editor-in-Chief

Just before the publication of this issue of “Cli- nical Diabetology”, the largest diabetes meeting in the world — 79th Scientific Sessions of the American Diabetes Association (ADA) — was held on June 7–11, 2019 in San Francisco, USA. During this congress, all clinical and scientific aspects of diabetes were raised in countless lectures, oral presentations and poster sessions. It is impossible to mention all of them, but I would like to draw your attention to the reports of the greatest interest of the congress participants. These were the reports presenting detailed analysis of the results of large clinical trials, such as PIONEER, REWIND, DECLARE-TIMI 58, CREDENCE, CAROLINA, assessing potential cardio- and nephroprotective effects of new classes of antidiabetic drugs, such as SGLT2 inhibitors or GLP1 analogs, as well as the cardiovascular and re- nal safety of linagliptin compared with a sulfonylurea.

Thanks to these trials we now know for certain that the drugs assessed are safe in terms of cardiovascular and renal function in different patient populations. In addition, the analysis of the results of the CREDENCE study with canagliflozin, for the first time since the proven nephroprotective effect of RAA blockers, ACE inhibitors and sartans, proved that this is another nephroprotective drug for diabetic patients. Soon, we will also learn about the results of the trials assessing kidney function in patients treated with two other SGLT2 inhibitors, dapagliflozin and empagliflozin, which are also expected to confirm the class effect in this respect. This would allow the indications for their use in everyday practice to be extended. In addition, the results of the DECLARE-TIMI 58 trial showed that dapagliflozin therapy is associated with benefits in primary prevention of heart failure in diabetes, a com- plication that until recently was underestimated and now is considered as one of the major challenges of

modern medicine due to the increasing number of affected patients.

It should also be stressed here that this issue is being released in convergence with the next, large and very important scientific meeting of our community

— the 20th Scientific Congress of Diabetes Poland that this year was held on May 16–18, in Lublin. During this meeting, apart from the very high scientific level, there was also space for interesting cultural events.

Among papers included in this issue of “Clinical Diabetology”, there is a particularly interesting paper by the authors from Egypt who discuss the correlations between microangiopathic complications in type 2 dia- betes. Another article that is worth mentioning is the article about the DAWN (Diabetes Attitudes, Wishes and Needs) study. This article does not address the most fre- quently discussed aspects of organic complications in diabetes but focuses on the mental sphere of patients.

This very issue of “Clinical Diabetology” is special to me because this is my last issue as Editor-in-Chief.

Managing “Clinical Diabetology” was a great adventu- re to me and now I am handing over the helm to the person who guarantees the further development of our journal, and, what I deeply believe, will soon introduce

“Clinical Diabetology” into the PubMed and MEDLINE databases and then into a list of journals indexed in the ISI databases, Master Journal List, known in Po- land as the Philadelphia List. The next Editor-in-Chief, appointed to this honorable position by the newly elected Main Board of Diabetes Poland, is Professor Leszek Czupryniak.

As usual, I would like to thank all the authors for submitting so many interesting manuscripts and I encourage you to further cooperation with the new Editor-in-Chief of “Clinical Diabetology”, a journal that is constantly growing thanks to your support.


Prof. Janusz Gumprecht

Dear Colleagues,


Powiązane dokumenty

Podobnie można interpretować uzyskane przez autorów niniejszej pracy wyniki w kontekście rezul- tatów badania Fabian i wsp., przeprowadzonego w grupie 355 chorych na cukrzycę typu

Walny Zjazd Członków Polskiego Towarzystwa Diabetologicznego odbył się w Łodzi 23 maja 2003 roku podczas IX Zjazdu PTD.. Zebraniu

The primary endpoint, consisting of the first heart fai- lure incident (need for an urgent outpatient appointment or hospital admission due to the intensity of heart failure

Professor Janusz Gumprecht has excellently developed the journal — it appears regularly, contains more and more papers from outside Poland, is included in the Web of Science

Although more than 3,500 years have passed since the first description of the symptoms of diabetes in the Egyptian papyrus dated to around 1550 BC, diabetes is still

differences in the frequency, causes and duration of hospitalization of children with diabetes in different regions of Poland, which implies the need to ensure uniform access

Another challenge is effective and safe use of antidiabetic drugs to minimize side effects, improve adherence, increase the acceptance of the disease and reduce the risk

At the beginning of October, annual meeting of European Association for the Study of Diabetes (EASD) will be held in Berlin, and one of the most awaited events during this

Among papers included in this issue of “Clinical Diabetology”, it is worth paying attention to a multi- centre study conducted in 2013–2017 in women with type 1 diabetes who,

As the practical management of patients with diabetes should be based primarily on knowledge derived from Evidence Based Medicine (EBM), the reference to the EBM

I would like to draw your attention to the problem of diabetes care quality discussed by researchers from Libya, an interesting case report of the use of hydroxychloroquine in type

Many interesting reports presented during the Congress addressed, among others, epidemiology, new possibilities of molecular biology, measurable effects of translating basic

Following the publication of the results of already completed Cardiovascular Outcome Trials (CVOTs) on new molecules used in the treatment of diabetes, there is no doubt that

In the InTandem3 study (Study to Evaluate the Safety of So- tagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) with

In addition to attending the scientific meetings, I also encourage you to read the latest issue of the “Clinical Diabetology”, where, among a number of interesting articles, I would

Considering the above, I would like to draw your attention to two of many interesting articles published in the last issue of Clinical Diabetology: the paper presenting

In accordance with other diabetic organizations (the American Diabetes Association — ADA, the National Institute for Health and Care Excellence — NICE), glycaemic goals has

Here, it should be mentioned that also the LEADER trial, that assessed cardiovascular safety of one of GLP-1 agonists, liraglutide, in the population of type 2 diabetes

Despite recent advances in medicine, introduction of new hypoglycaemic drugs and the fact that more than 3.500 years have passed since the earliest known record of diabetes

The conference brought together a group of distinguished lecturers and almost 500 participants — physicians dealing in their everyday practice with carbohydrate

At the same time, we intend to continue the educational function of the journal and we do not want to hinder the access to its content for the readers; therefore, we decided

This change is a result of systematic de- velopment of our journal aiming at further increasing its presence and importance on the international arena and striving to

„Rodzina w systemie wsparcia społecznego i pomocy osobom z problemem alkoholowym”, zorganizowana przez Pracownię Pedagogiki Specjalnej, w ramach realizowanego